GPRC5D: The Next Frontier for Immunotherapy in Multiple Myeloma, With Drs. Shaji Kumar and Saad Usmani

In this installment, The Hematologist Editor-in-Chief Dr. Shaji Kumar has a conversation with Contributing Editor Dr. Saad Usmani. They discuss Dr. Usmani’s Year’s Best coverage in which he describes the past year’s breakthroughs in immunotherapies for multiple myeloma. The focus in particular on B-cell maturation antigen (BCMA) –targeted therapies, including chimeric antigen receptor T-cells (CAR-Ts) and bispecific T-cell engagers. The editors discuss data presented as recently as the 2022 ASH Annual Meeting, as well as issues surrounding toxicity, patient relapse, and the future of bispecifics and CAR-Ts.

You can access his article online at
https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V20.1.202314/494129/GPRC5D-The-Next-Frontier-for-Immunotherapy-in
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/ 

What is The Hematologist?

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.